Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and Obesity
<i>Background and Objectives</i>: The <i>NUCB2</i> gene and its polymorphisms were identified as novel players in the regulation of food intake, potentially leading to obesity (OBE) and altered eating behaviors. Naltrexone/bupropion SR (NB) showed good efficacy and tolerabili...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/2/451 |
| _version_ | 1797298860932988928 |
|---|---|
| author | Elvira Anna Carbone Mariarita Caroleo Marianna Rania Renato de Filippis Francesca Condoleo Federica Catalano Matteo Aloi Pasquale De Fazio Franco Arturi Marta Letizia Hribal Teresa Vanessa Fiorentino Cristina Segura-Garcia |
| author_facet | Elvira Anna Carbone Mariarita Caroleo Marianna Rania Renato de Filippis Francesca Condoleo Federica Catalano Matteo Aloi Pasquale De Fazio Franco Arturi Marta Letizia Hribal Teresa Vanessa Fiorentino Cristina Segura-Garcia |
| author_sort | Elvira Anna Carbone |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: The <i>NUCB2</i> gene and its polymorphisms were identified as novel players in the regulation of food intake, potentially leading to obesity (OBE) and altered eating behaviors. Naltrexone/bupropion SR (NB) showed good efficacy and tolerability for treating OBE and altered eating behaviors associated with binge eating disorder (BED). This prospective study investigates the influence of <i>NUCB2</i> gene polymorphism on NB treatment response in OBE and BED. <i>Materials and Methods</i>: Body mass index (BMI), eating (EDE-Q, BES, NEQ, GQ, Y-FAS 2.0) and general psychopathology (BDI, STAI-S) were evaluated at baseline (t0) and after 16 weeks (t1) of NB treatment in patients with OBE and BED (Group 1; <i>N</i> = 22) vs. patients with OBE without BED (Group 2; <i>N</i> = 20). Differences were evaluated according to the rs757081 <i>NUCB2</i> gene polymorphism. <i>Results</i>: <i>NUCB2</i> polymorphism was equally distributed between groups. Although weight at t0 was higher in Group 1, weight loss was similar at t1 in both groups. BMI was not influenced by <i>NUCB2</i> polymorphism. In Group 1, the CG-genotype reported significant improvement in eating psychopathology while the GG-genotype reported improvement only for FA. No differences were observed in Group 2. <i>Conclusions</i>: Patients diagnosed with BED and treated with NB exhibited a more favorable treatment response within the CG-genotype of the <i>NUCB2</i> polymorphism. |
| first_indexed | 2024-03-07T22:41:10Z |
| format | Article |
| id | doaj.art-f798a7f45dd94232a3ea8c603a3264de |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-07T22:41:10Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-f798a7f45dd94232a3ea8c603a3264de2024-02-23T15:08:53ZengMDPI AGBiomedicines2227-90592024-02-0112245110.3390/biomedicines12020451Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and ObesityElvira Anna Carbone0Mariarita Caroleo1Marianna Rania2Renato de Filippis3Francesca Condoleo4Federica Catalano5Matteo Aloi6Pasquale De Fazio7Franco Arturi8Marta Letizia Hribal9Teresa Vanessa Fiorentino10Cristina Segura-Garcia11Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyCenter for Clinical Research and Treatment of Eating Disorders, University Hospital Renato Dulbecco, 88100 Catanzaro, ItalyDepartment of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, ItalyDepartment of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy<i>Background and Objectives</i>: The <i>NUCB2</i> gene and its polymorphisms were identified as novel players in the regulation of food intake, potentially leading to obesity (OBE) and altered eating behaviors. Naltrexone/bupropion SR (NB) showed good efficacy and tolerability for treating OBE and altered eating behaviors associated with binge eating disorder (BED). This prospective study investigates the influence of <i>NUCB2</i> gene polymorphism on NB treatment response in OBE and BED. <i>Materials and Methods</i>: Body mass index (BMI), eating (EDE-Q, BES, NEQ, GQ, Y-FAS 2.0) and general psychopathology (BDI, STAI-S) were evaluated at baseline (t0) and after 16 weeks (t1) of NB treatment in patients with OBE and BED (Group 1; <i>N</i> = 22) vs. patients with OBE without BED (Group 2; <i>N</i> = 20). Differences were evaluated according to the rs757081 <i>NUCB2</i> gene polymorphism. <i>Results</i>: <i>NUCB2</i> polymorphism was equally distributed between groups. Although weight at t0 was higher in Group 1, weight loss was similar at t1 in both groups. BMI was not influenced by <i>NUCB2</i> polymorphism. In Group 1, the CG-genotype reported significant improvement in eating psychopathology while the GG-genotype reported improvement only for FA. No differences were observed in Group 2. <i>Conclusions</i>: Patients diagnosed with BED and treated with NB exhibited a more favorable treatment response within the CG-genotype of the <i>NUCB2</i> polymorphism.https://www.mdpi.com/2227-9059/12/2/451<i>NUCB2</i>polymorphismnesfatin-1binge eating disorderobesityfood addiction |
| spellingShingle | Elvira Anna Carbone Mariarita Caroleo Marianna Rania Renato de Filippis Francesca Condoleo Federica Catalano Matteo Aloi Pasquale De Fazio Franco Arturi Marta Letizia Hribal Teresa Vanessa Fiorentino Cristina Segura-Garcia Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and Obesity Biomedicines <i>NUCB2</i> polymorphism nesfatin-1 binge eating disorder obesity food addiction |
| title | Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and Obesity |
| title_full | Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and Obesity |
| title_fullStr | Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and Obesity |
| title_full_unstemmed | Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and Obesity |
| title_short | Influence of <i>NUCB</i>/Nesfatin-1 Polymorphism on Treatment Response to Naltrexone/Bupropion SR in Binge Eating Disorder and Obesity |
| title_sort | influence of i nucb i nesfatin 1 polymorphism on treatment response to naltrexone bupropion sr in binge eating disorder and obesity |
| topic | <i>NUCB2</i> polymorphism nesfatin-1 binge eating disorder obesity food addiction |
| url | https://www.mdpi.com/2227-9059/12/2/451 |
| work_keys_str_mv | AT elviraannacarbone influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT mariaritacaroleo influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT mariannarania influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT renatodefilippis influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT francescacondoleo influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT federicacatalano influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT matteoaloi influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT pasqualedefazio influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT francoarturi influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT martaletiziahribal influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT teresavanessafiorentino influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity AT cristinaseguragarcia influenceofinucbinesfatin1polymorphismontreatmentresponsetonaltrexonebupropionsrinbingeeatingdisorderandobesity |